A randomized , single-blinded , placebo-controlled trial was performed on 25 subjects : 17 subjects received ATG ( 2.5 mg/kg intravenously ) followed by pegylated G-CSF ( 6 mg subcutaneously every 2 weeks for 6 doses ) and 8 subjects received placebo .